Rhythm Pharmaceuticals (RYTM) Change in Accured Expenses (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has reported Change in Accured Expenses for 11 consecutive years, with -$5.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 54.64% year-over-year to -$5.6 million; the TTM figure through Mar 2026 stood at $19.9 million (up 1.9% YoY), while the FY2025 annual figure was $21.9 million, changed 0.12% from the prior year.
• Change in Accured Expenses fell to -$5.6 million in Q1 2026 per RYTM's latest filing, from $1.3 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $15.7 million in Q4 2022 and bottomed at -$12.6 million in Q3 2022.
• Historically, Change in Accured Expenses has averaged $3.2 million across 5 years, with a median of $1.3 million in 2025.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses slumped 309.83% — and 2023, when it soared 9849.06%.
• Rhythm Pharmaceuticals' Change in Accured Expenses stood at $15.7 million in 2022, then plunged by 69.08% to $4.9 million in 2023, then soared by 212.45% to $15.2 million in 2024, then tumbled by 91.73% to $1.3 million in 2025, then tumbled by 547.65% to -$5.6 million in 2026.
• Business Quant data shows RYTM's Change in Accured Expenses at -$5.6 million in Q1 2026, $1.3 million in Q4 2025, and $11.0 million in Q3 2025.